Skip to main content
. 2009 Dec 29;5:1033–1042. doi: 10.2147/vhrm.s6412

Table 1.

Summary of JUPITER and AURORA trial results

Endpoint Rosuvastatin rates per 100 person-year Placebo rates per 100 person-year Relative risk reduction % P value
JUPITER results N = 8901 N = 8901
Primary endpoint 0.77 1.36 44 <0.00001
Nonfatal MI 0.12 0.33 65 <0.00001
Nonfatal stroke 0.16 0.31 48 0.003
Arterial revasc 0.38 0.71 46 <0.0001
MI, stroke, and CV death 0.45 0.85 47 <0.00001
Death from any cause 1 1.25 20 0.02
AURORA results N = 1389 N = 1384
Primary endpoint 9.2 9.5 4 0.59
Nonfatal MI 2.1 2.5 16 0.23
Nonfatal stroke 1.2 1.1 NA 0.42
Death from CV cause 7.2 7.3 0 0.97
Death from any cause 13.5 14 4 0.51
Death from non-CV causes 5.5 6 8 0.34

Abbreviations: MI, myocardial infarction; revasc, revascularizations; CV, cardiovascular.